Here are relevant reports on : personalized-medicine-market
-
In Vitro Lung Model Market by Type (2D, 3D (In-house, Commercial)), Application (Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine) - Global Forecasts to 2023
The lung in vitro models market is projected to reach USD 427.4 Million by 2023, at a CAGR of 17.5%. The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, advancements in Cell Culture technologies, and the development of new 3D in vitro models. The major players in the Lung in vitro models market include Epithelix (Switzerland), MatTek Corporation (US), Lonza (Switzerland), ATCC (US), InSphero (Switzerland), Emulate (US), AlveoliX (Switzerland), Oncotheis (Switzerland), Insphero (Switzerland), TissUse (Switzerland), Mimetas (Netherlands), and CN Bio Innovations (UK).
- Published: April 2018
- Price: $ 11000
- TOC Available:
-
Precision Medicine Software Market by Delivery Mode (On-Premise & Cloud-Based), End User (Healthcare Providers, Research Centers & Government Institutes, Pharmaceutical & Biotechnology Companies), Application, and Region - Global Forecast to 2024
The precision medicine software market is projected to reach USD 2.0 billion by 2024, at a CAGR of 11.5%. Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine software market. However, the high cost of deployment, issues related to the secure storage of large volumes of sequenced data, lack of reimbursement for precision medicine-based treatments, and the dearth of skilled IT professionals in healthcare are expected to restrain market growth to a certain extent in the coming years. Syapse, Inc. (US), 2bPrecise LLC (Israel), Foundation Medicine, Inc. (US), Fabric Genomics (US), SOPHiA GENETICS SA (Switzerland), PierianDx, Inc. (US), N-of-One, Inc. (US), Human Longevity, Inc. (US), Translational Software, Inc. (US), Sunquest Information Systems Inc. (US), Gene42, Inc. (Canada), LifeOmic Health, LLC (US), NantHealth, Inc. (US), Tempus Labs, Inc. (US), Flatiron Health, Inc. (US), IBM Watson Group (US), and Koninklijke Philips N.V. (Netherlands)
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019
The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
- Published: September 2014
- Price: $ 4950
- TOC Available:
-
Advanced Visualization Market by Type (Enterprise, Standalone), Modality (MRI, CT, PET, Ultrasound, Radiotherapy, Nuclear Medicine), Application (Radiology, Oncology, Neuro), End User (Hospital, ASC, Diagnostic Center) & Region - Global Forecast to 2029
The global advanced visualization market, valued at US$3.36 billion in 2023, stood at US$3.78 billion in 2024 and is projected to advance at a resilient CAGR of 11.7% from 2024 to 2029, culminating in a forecasted valuation of US$6.55 billion by the end of the period. Technological advancements in advanced visualization tools, the rising need for early detection of diseases, and the growing support from government & private organizations are key factors driving the market growth.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Fluorometer Market by Light source (Lamps, LEDs, Diode Lasers, and Lasers), Application (Chemistry/Biochemistry, Medicine & Others), and End User (Hospitals, Pharmaceutical and Biotechnology Firms & CROs, Others) - Global Forecast to 2023
The global Fluorometer market is expected to reach USD 668.2 million by 2023 from USD 521.1 million in 2018, growing at a CAGR of 5.1%. Increasing incidence of cancer, advancement in cancer diagnostics, technological advancement in fluorometry are some of the major factors driving the growth of the global fluorometer market. These driving factors consequence to the rapid adoption of these new devices, thus propelling the market growth.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030
The global nuclear medicine software market, valued at US$887.5million in 2024, stood at US$970.0 million in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of US$1,491.5 million by the end of the period. This growth is mainly driven by the increasing demand for early and accurate diagnostics, as precision imaging is essential for treatment planning.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Electroceuticals Market / Bioelectric Medicine Market by Product (Cardiac Pacemakers, ICD, Cochlear Implant, Neuromodulation (Deep Brain Stimulation)), Type (Implantable, Non-Invasive), Application (Arrhythmia, Heart Failure, Epilepsy) & Region - Global Forecast to 2029
The global electroceuticals market, valued at US$21.9 billion in 2023, stood at US$23.9 billion in 2024 and is projected to advance at a resilient CAGR of 7.0% from 2024 to 2029, culminating in a forecasted valuation of US$33.6 billion by the end of the period. Growth of the overall market is largely driven by the increasing incidence of cardiovascular, hearing loss and neurological disorders, increasing research in these field of disorders, and rising awareness regarding electroceuticals devices.
- Published: March 2024
- Price: $ 4950
- TOC Available:
-
AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030
The global AI in Precision Medicine market, valued at US$0.60 billion in 2023, stood at US$0.78 billion in 2024 and is projected to advance at a resilient CAGR of 30.7% from 2024 to 2030, culminating in a forecasted valuation of US$3.92 billion by the end of the period. Growth in precision medicine, AI’s efficiency in drug discovery, integration of Real-World Evidence (RWE) in emerging markets to drive the market significantly.
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Thyroid, Cardiology), Procedures - Forecasts to 2020
Over the years, the European nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The European radiopharmaceuticals market is witnessing growth owing to an increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 radioisotopes are estimated to contribute the highest to the European nuclear medicine diagnostic market in 2015, whereas Ra-223, I-131 and Y-90 ensured their leading position in the therapeutic market. The European nuclear medicine/radiopharmaceuticals market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, growing at a CAGR of 8.2% from 2015 to 2020.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application (Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029
The global 3D bioprinting market, valued at US$1.2 billion in 2023, stood at US$1.3 billion in 2024 and is projected to advance at a resilient CAGR of 12.7% from 2024 to 2029, culminating in a forecasted valuation of US$2.4 billion by the end of the period. The market growth is fueled by the growing adoption of 3D bioprinting technology in the pharmaceutical and cosmetic industries, technological advancements in 3D bioprinting, and the rising demand for organ transplants.
- Published: May 2024
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
